In this study conducted on 26 osteosarcoma patients the level of ECD/HER-2 in serum measured using the immunoenzymatic method before initial chemotherapy ranged between 3.8 and 14.4 ng/ml with a median of 5 ng/ml. Here, ERBB2 is linked to osteosarcoma.